At week 16, 64.7% of patients achieved IGA scores of 0/1, with further improvement to 74.1% at week 24. How does this compare to existing therapies for moderate-to-severe plaque psoriasis, particularly in terms of speed and magnitude of skin clearance?

Nearly 65% of icotrokinra-treated patients achieved PASI-90 by week 24. How transformative is achieving PASI-90 for patients with plaque psoriasis in improving their quality of life and reducing disease burden?

The safety profile of icotrokinra appears consistent with earlier trials, with similar adverse event rates to placebo. How significant is this in positioning icotrokinra as a safe option for long-term management of psoriasis?

The ICONIC-TOTAL study demonstrated efficacy in plaque psoriasis affecting challenging areas. How important is this for addressing unmet needs in these difficult-to-treat cases?

As an oral therapy, icotrokinra offers a non-invasive alternative to injections or infusions. How does this benefit patients in terms of treatment adherence and accessibility?

Given icotrokinra's targeted IL-23 receptor blockade and oral delivery, how does it compare to current biologic options in efficacy, safety, and convenience?

Icotrokinra is being evaluated for other IL-23-mediated conditions, including ulcerative colitis. How promising is this therapy as a versatile treatment across multiple inflammatory diseases?

With plans for NDA submission in 2025 and additional trials in ulcerative colitis and psoriatic arthritis, what challenges and opportunities do you foresee in icotrokinra's path to approval and commercialization?